Kyverna Therapeutics Highlights KYV-101's Promise for Neuroinflammatory Diseases at ECTRIMS 2024

Kyverna Therapeutics, Inc., a biopharmaceutical company specializing in cell therapies for autoimmune diseases, has presented significant new findings at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark. These findings, shared through three posters and a company-sponsored symposium, underscore the initial efficacy and safety of KYV-101, a CAR T-cell therapy, across various neuroinflammatory diseases, with a focus on stiff-person syndrome, myasthenia gravis, and multiple sclerosis.

In a detailed symposium, Kyverna highlighted case reports from 11 patients treated with KYV-101. The case reports indicated positive outcomes, such as improved mobility and reduced autoantibody levels in stiff-person syndrome, sustained disease control in myasthenia gravis, and a significant reduction in oligoclonal bands in multiple sclerosis patients who had not responded to previous anti-CD20 medications. Notably, some benefits extended beyond one year post-infusion, emphasizing the durability of KYV-101's effects.

Ralf Gold, M.D., a professor at Ruhr University Bochum and symposium presenter, remarked on how the new data could redefine treatment efficacy and support KYV-101's safety profile. Warner Biddle, Kyverna's CEO, expressed pride in their leading role in understanding B-cell reset's potential in treating neuroinflammatory diseases. Biddle also highlighted the promising results in multiple sclerosis, a condition with high unmet medical needs, and the potential for KYV-101 to transform treatment for these severe diseases.

Kyverna is currently conducting three Phase 2 clinical trials for KYV-101 across different neuroinflammatory conditions: KYSA-6 in myasthenia gravis, KYSA-7 in multiple sclerosis, and KYSA-8 in stiff-person syndrome. The ongoing evaluation aims to solidify KYV-101's position as a transformative treatment option. In addition to these trials, Kyverna's presentation at ECTRIMS included three posters detailing the design and methods of their clinical trials, focusing on the activity and manufacturing of KYV-101, as well as specific studies for myasthenia gravis and multiple sclerosis.

The symposium and poster presentations at ECTRIMS provided a platform for Kyverna to share detailed clinical insights. The case reports from the symposium outlined specific patient outcomes:
- In stiff-person syndrome, two patients exhibited improved mobility and reduced autoantibody levels, with one patient maintaining benefits beyond a year post-infusion.
- In myasthenia gravis, three patients demonstrated reduced anti-AChR antibody levels and sustained disease control, with two patients maintaining these benefits for over a year.
- In multiple sclerosis, five patients who had not responded to previous treatments showed a notable reduction in CNS oligoclonal bands.

Across all patients treated with KYV-101 to date, no severe cases of cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) were observed, underscoring the therapy's safety profile.

Kyverna's innovative approach with KYV-101, leveraging CAR T-cell technology, presents a promising new direction in treating B cell-driven autoimmune diseases. Their continuous research and clinical trials aim to provide durable and transformative treatment options for patients suffering from debilitating neuroinflammatory conditions.